Researchers reviewed how polygenic methylation patterns affect the effectiveness of osimertinib, a medication used to treat non-small cell lung cancer. The study looked at how these chemical changes to DNA and RNA might help cancer cells resist treatment. Specifically, the review looked at how these patterns impact drug target mutations, transporter functions, and internal signaling pathways.
The findings suggest a link between these methylation patterns and the development of drug resistance. While the study identifies these patterns as potential targets for new treatments, the exact ways these processes work are not yet fully understood. Because the research is a systematic review, it provides a theoretical framework rather than specific clinical trial results.
Patients and doctors should view these findings as early evidence of how cancer cells adapt. While these patterns could lead to new treatment strategies in the future, they do not currently offer a new clinical protocol. The research highlights the importance of understanding the interaction between DNA methylation and other resistance mechanisms.
